This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Discoidin domain receptor tyrosine kinase 1 (DDR1)	Rat and <i>in vitro</i> studies identified inhibitors of DDR1 that could help treat cancer. In <i>in vitro</i> assays, compounds from a class of 3-(2-(pyrazolo[1,5-<i>a</i>]pyrimidin-6-yl)ethynyl)benzamides inhibited DDR1 with low nanomolar potency. In a panel of human cancer cell lines with high DDR1 expression, the lead molecules inhibited cell growth. In rats, the inhibitors showed high oral bioavailability and good pharmacokinetics. Next steps include studying the molecules in animal models of cancer. SciBX 6(14); doi:10.1038/scibx.2013.333 Published online April 11, 2013	Patent application filed; available for licensing	Ding, K. <i>et al. J. Med. Chem.</i>; published online March 22, 2013; doi:10.1021/jm301824k Contact: Yong Xu, Chinese Academy of Sciences, Guangzhou, China e-mail: tu_zhengchao@gibh.ac.cn Contact: Ke Ding, same affiliation as above e-mail: ding_ke@gibh.ac.cn